According to a report released by QuintilesIMS Institute last month, health care systems are having difficulties in keeping up with the rapid pace of innovation and information in the biopharmaceuticals industry. The report suggests that more intelligent analytics be applied to cross-industry datasets to help advance drug development and commercialization. The report calls for a transformation of clinical research (i.e., more efficient execution of clinical trials, improved patient-targeting, etc.) that in turn can improve outcomes for patients, such as their standards for care and treatment, and increase the market value for medicines. The nine evidence-based approaches presented by the report that could enhance the collection and interpretation of datasets to accelerate drug development consist of: identifying exact potential indications and target endpoints in clinical studies; refining the criteria for patient targeting; improving the locations where clinical trials are held; using risk-based monitoring to execute clinical trials; collecting a wide source of medical data to better drive patient care and treatment solutions; boosting patient adherence levels in medication usage; providing appropriate medications to patients and physicians; demonstrating medical value for patients; and using post-market information to bridge gaps in cross-industry data and to predict market trends. The report accentuates that data should not be a limited resource and should cross organizational boundaries, and that evidence-based portfolios would better indicate the value of new medicines to health care investors in the biopharmaceuticals industry. Future challenges of cross-industry datasets include data privacy, data transparency and collaboration of data technology.

Source: QuintilesIMS Institute

< | >